Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3711 - HER2 overexpression and amplification in patients with colorectal cancer (HOLIC): A large-scale retrospective study in Chinese population


09 Sep 2017


Poster display session


Translational Research;  Colon and Rectal Cancer


Shujuan NI


Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393


S. NI1, J. Peng2, D. Huang1, H. Sun1, L. Wang1, C. Tan1, J. Cai2, W. Sheng1

Author affiliations

  • 1 Pathology, Fudan University Shanghai Cancer Center, 200032 - Shanghai/CN
  • 2 Colorectal Surgery, Fudan University Shanghai Cancer Center, 200032 - Shanghai/CN


Abstract 3711


HER2 overexpression or amplification may be a potentially predictive factor for anti-HER2 response and anti-EGFR resistance in colorectal cancer (CRC). However, the prevalence of HER2 positivity in CRC patients and its correlation with clinicopathologic features are not clear.


HER2 and MMR protein expression were tested by immunohistochemistry (IHC) in formalin-fixed, paraffin-embedded samples from 4,913 consecutive CRC patients treated with surgical resection during 2011-2014 in our institution. Dual color silver-enhanced in situ hybridization (DISH) was performed in all IHC 3+/2+ cases. The scoring criteria of HER2 status in gastric cancer was used. RAS/BRAF mutation status was assessed by Sanger DNA sequencing.


HER2 positivity was found in 160/4,913 (3.3%) cases, including 68 cases (42.5%) with IHC 3+ and 92 cases (57.5%) with IHC 2+/DISH+. HER2 positivity was more common in younger patients (


To our knowledge, this is the largest study of HER2 status in Asian patients with CRC. HER2 positivity occurred in a small number of patients with CRC, related to unfavorable prognostic factors, more common in younger patients and rare in MMR deficiency cases. Compared with previous results in western population, the RAS/BRAF mutation rate of HER2 positive Chinese CRC patients seems much higher. The further study regarding molecular information of these HER2 positive CRC patients is ongoing.

Clinical trial identification

Legal entity responsible for the study

Fudan University Shanghai Cancer Center




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.